People with late-onset Pompe disease (LOPD) rarely have genetic variations in genes that are important for making glycogen in…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A surgical technique called conjoint fascial sheath (CFS) suspension may help relieve drooping eyelids in children with infantile-onset Pompe…
After two years being treated with AT-GAA (cipaglucosidase alfa/miglustat), adults with …
Nearly three years of treatment with Nexviazyme (avalglucosidase alfa) led to long-term improvements…
Three siblings with Pompe disease caused by the same mutations were described in a recent report. Despite all having…
Regulatory authorities in the U.S. and the U.K. are expected to decide in the third quarter of this year whether…
Researchers in Taiwan have developed new molecules that can stabilize the acid alpha-glucosidase (GAA) enzyme, a strategy they say might…
MRI scans of people with classic infantile Pompe disease showed a change in the microscopic structure of certain brain…
MZE001, an experimental oral substrate reduction treatment for Pompe disease, was well-tolerated in both single and multiple doses in…
Newborn screening for Pompe disease is feasible at large scale and can facilitate early treatment with better outcomes for…